anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
<P>PROBLEM TO BE SOLVED: To provide a transparent base material having a transparent external appearance, good brightness (gloss), hardness, usability, texture (smooth, well speadable, and unsticky), color effect, gloss effect, moisturizing effect, and good durability of these effects.  <P>SOLUTION: The gelling agent composition includes an N-acyl-L-acidic amino acid dialkylamide and a sugar fatty acid ester which is liquid at ordinary temperatures and/or a polyol fatty acid ester. In preparing the transparent base, the gelling agent composition can be dissolved at a low temperature of not higher than 100°C to enable the preparation of the transparent base excellent in stability without causing syneresis with time or in a high temperature state, a waste liquid, and sweating, and excellent in brightness (gloss), a feeling of use, and a feeling of finishing. The obtained transparent base excels in external appearance such as transparency, brightness (gloss), and color developability and can be suitably used in various applications such as a texture, a feeling of use, a moisturizing effect, coloring intensity and durability thereof. The transparent base can be used in a lip cream, a lip gloss agent, a lip color gloss agent, and the like.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Certain embodiments of the present invention provide a method (200) for clinical presentation of a radiological study including: associating a customizable set of rules (302, 305, 306, 400) with image data corresponding to at least a portion of the radiological study; and rendering automatically the image data to form volumetric data; and navigating automatically the volumetric data with the customizable set of rules (302, 304, 306, 400) to present a navigated the at least a portion of the radiological study to a user. In an embodiment, the system (100) further includes halting the navigating automatically the volumetric data from an interaction by the user. In an embodiment, the rendering automatically the image data is initiated from an interaction by the user. In an embodiment, the navigating automatically the volumetric data is initiated from an interaction by the user. In an embodiment, both the rendering automatically the image data and the navigating automatically the volumetric data are initiated an interaction by the user. In an embodiment, the customizable set of rules (302, 304, 306, 400) includes at least one of: a rendering rule and a navigation rule.
In some example embodiments, the present invention relates to a system for providing therapy to a body. The system includes a first patch that applies a first therapy to the body when the first patch is placed near the body. The first patch is customized to fit on a first area of the body. The system further includes a second patch that applies a second therapy to the body when the second patch is placed near the body. The second patch may be a different size than the first patch such that the second patch is customized to fit on a second area of the body and is detachably secured to the first patch to form a third patch that is a combination of the first patch and the second patch. In some embodiments, the first therapy may be different than the second therapy.
BACKGROUND: Observational studies have indicated a link between autoimmune liver diseases (AILD) and chronic hepatitis B (CHB) through observational studies. The association between AILD and CHB remains indeterminate.
METHODS: A two-sample Mendelian randomization (MR) analysis was conducted to scrutinize the causal nexus between AILD and CHB utilizing summary statistics derived from extensive genome-wide association studies (GWASs) in European populations. The primary statistical methodology employed was the inverse variance-weighted (IVW) method to deduce the causal connection of AILD on CHB. This study incorporated primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) as subtypes of AILD. Additionally, we conducted a multivariable MR (MVMR) analysis to account for the potential confounding effects of smoking, alcohol consumption, body mass index (BMI), and some autoimmune diseases.
RESULTS: Our MR investigation encompassed a cohort of 725,816 individuals. The MR analysis revealed that genetically predicted PSC significantly correlated with a reduced risk of CHB (IVW OR = 0.857; 95%CI: 0.770-0.953, P = 0.005). Conversely, the reverse MR analysis suggested that genetic susceptibility to PSC might not modify the risk of CHB (IVW OR = 1.004; 95% CI: 0.958-1.053, P = 0.866). Genetically proxied PBC and AIH exhibited no discernible causal association with CHB in the MR analysis using the IVW method (P = 0.583; P = 0.425). The MVMR analysis still indicated a decreased risk of CHB associated with PSC (OR = 0.853, P = 0.003).
CONCLUSION: Our study elucidates a causal relationship between PSC and a diminished risk of CHB.
The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use the Hedia Diabetes Assistant bolus calculator with the physical activity module (intervention) during a 24-hour period starting one hour before the bout of exercise.
BACKGROUND: The popularity of online health information seeking (OHIS) has increased significantly owing to its accessibility and affordability. To facilitate better health management, it is essential to comprehend the generational differences in OHIS behavior and preventative health actions after seeking online health information (OHI).
OBJECTIVE: This study investigates the variations in OHIS and engagement in preventative health actions between 2 generations based on their technology use (digital natives [aged 18-42 years] and digital immigrants [aged ≥43 years]). Additionally, this research explores the mediating role of OHIS types on the generational effect on preventative health actions and the moderating role of OHI search frequency, gender, and the presence of chronic diseases on the generational effect on OHIS types and preventative health actions.
METHODS: A preregistered online survey was conducted on the Prolific online data collection platform using stratified sampling of 2 generations (digital natives and digital immigrants) from the United States in November 2023. Overall, 3 types of OHIS were collected: health wellness information search, health guidance information search, and health management information search. A 1-way analysis of covariance tested the generational differences in types of OHIS and preventative health actions, and a 2-way analysis of covariance tested the moderating role of OHIS search frequency, gender, and the presence of chronic diseases using 7 control variables. The PROCESS Macro Model 4 was used to conduct mediation analyses, testing OHI search types as mediators. Linear regression analyses tested age as a predictor of OHIS and preventative health actions.
RESULTS: The analysis of 1137 responses revealed generational differences in OHIS. Digital natives searched for health wellness information more frequently (P<.001), whereas digital immigrants searched for health guidance (P<.001) and health management information (P=.001) more frequently. There were no significant differences between the 2 generations regarding preventative health actions (P=.85). Moreover, all 3 types of OHIS mediated the relationship between generational differences and preventative health actions. Furthermore, as people aged, they searched for significantly less health wellness information (P<.001) and more health guidance (P<.001), and health management information (P=.003). Age was not a significant predictor of preventative health actions (P=.48). The frequency of OHI searches did not moderate the effect of generations on OHIS types and preventative health actions. Gender only moderated the relationship between generation and health guidance information search (P=.02), and chronic diseases only moderated the relationship between generation and health wellness information search (P=.03).
CONCLUSIONS: To the best of our knowledge, this study is the first to explore how 2 digital generations vary in terms of searching for OHI and preventative health behaviors. As the older adult population grows, it is crucial to understand their OHIS behavior and how they engage in preventative health actions to enhance their quality of life.
The primary hypothesis being tested in this study is that Ultravision facilitates the utilization of lower pneumoperitoneal pressures whilst maintaining an adequate visual field throughout the procedure with low demand for CO2 replenishment to maintain pneumoperitoneal pressure. Comparisons in terms of surgical field visualization, procedure times, and CO2 consumption will be conducted in order to determine whether or not any clinical benefits are derived from the use of the Ultravision™ System compared to the Airseal® iFS. Low pressure laparoscopy for this study is set at 10mmHg. This is a prospective, open-label, randomized controlled study. The study will include two study arms. Patients undergoing laparoscopic cholecystectomy will be randomized to either "Ultravision" (study arm 1) or Airseal® iFS (study arm 2). Both groups will conduct the procedure at 10mmHg, considered to be low pressure/low impact laparoscopic surgery. The study will enroll 30 patients, 15 per group. Both devices are being used according to their cleared label claims.
Obesity is associated with low-grade chronic inflammation and impaired glucose metabolism, both of which are detrimental to wound healing. C-C motif chemokine receptor 2 (CCR2) plays an important role in cell recruitment during healing, and our recent studies revealed the significance of CCR2-CCL2 signaling in promoting the proliferation of pro-inflammatory monocytes/macrophages in wounds. Therefore, we sought to determine whether diet-induced obesity increases monocyte/macrophage proliferation and their accumulation in skin wounds. We first confirmed that wound closure was delayed in obese CCR2RFP/+ mice fed with a high-fat diet (HFD) compared to mice fed with a normal diet (ND). Using in vivo imaging and flow cytometry analysis, we found that HFD mice had significantly increased accumulation of CCR2+ monocytes/macrophages, particularly pro-inflammatory CCR2+Ly6C+ cells in wounds compared to their ND counterparts. Importantly, HFD mice exhibited an increased proliferation of wound CCR2+Ly6C+ compared to ND mice. Together, our data suggest that obesity leads to an increased proliferation and accumulation of pro-inflammatory CCR2+Ly6C+ monocytes/macrophages in skin wounds, which may contribute to delayed healing.
The toxicity of amphotericin B liposome for injection due to overdose has not been defined. Repeated daily doses up to 10 mg/kg in pediatric patients and 15 mg/kg in adult patients have been administered in clinical trials with no reported dose-related toxicity. 

Management 

If overdosage should occur, cease administration immediately. Symptomatic supportive measures should be instituted. Particular attention should be given to monitoring renal function. Hemodialysis or peritoneal dialysis do not appear to significantly affect the elimination of amphotericin B liposome for injection.
The invention relates to the field of traditional Chinese medicine application and particularly discloses a traditional Chinese medicine for treating multiple sclerosis. The traditional Chinese medicine for treating multiple sclerosis is prepared from raspberries, agalma delavayi (Franch.) Hutch., cotton seeds, herb of variegate ladyslipper, rhizomes of whorledleaf solomonseal, melastoma polyanthum, concha arcae, astilboides tabularis, berchemia lineate, begonia palmate, platanthera chlorantha cust. ex Rchb, hygrophila salicifolia, ormosia henryi, all-grass of loureiro clematis, rhizomes of kirilow rhodiola, oxalis corniculata, isodon japonica var.galaucocalyx, licorice roots, radix geutianae, bile arisaema, purple flower holly leaves, hypericum japonicum, lysimachia fortunei maxim, clerodendron cyrtophyllum turcz., euphorbia hirta, melothria ndica Lour.Zehneria indica (Lour.) C. Y. Wu, pinnated brake herb, scirpus fluviatilis, radix saussureae lappae, stems of common stelmatocrypton and ranunculaceae clematis henryi, and the traditional Chinese medicine materials are mixed and prepared into the traditional Chinese medicine according to a certain weight proportion. The traditional Chinese medicine is easy to prepare, good in absorbing effect, long in medicine effect lasting time, remarkable in curative effect, free of side effects, high in safety and low in production cost, multiple sclerosis will not relapse after medicine withdrawal, and symptoms of patients can be alleviated easily.
Increased bone and tumor pain and, also, local disease flare have occurred, which are sometimes associated with a good tumor response. Patients with increased bone pain may require additional analgesics. Patients with soft tissue disease may have sudden increases in the size of preexisting lesions, sometimes associated with marked erythema within and surrounding the lesions and/or the development of new lesions. When they occur, the bone pain or disease flare are seen shortly after starting tamoxifen and generally subside rapidly.

In patients treated with tamoxifen for metastatic breast cancer, the most frequent adverse reaction to tamoxifen is hot flashes.

Other adverse reactions which are seen infrequently are hypercalcemia, peripheral edema, distaste for food, pruritus vulvae, depression, dizziness, light-headedness, headache, hair thinning and/or partial hair loss, and vaginal dryness.
This metaresearch study aimed to evaluate the completeness of reporting of prediction model studies in patients with spinal pain or osteoarthritis (OA) in terms of adherence to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement. We searched for prognostic and diagnostic prediction models in patients with spinal pain or OA in MEDLINE, Embase, Web of Science, and CINAHL. Using a standardized assessment form, we assessed the adherence to the TRIPOD of the included studies. Two independent reviewers performed the study selection and data extraction phases. We included 66 studies. Approximately 35% of the studies declared to have used the TRIPOD. The median adherence to the TRIPOD was 59% overall (interquartile range (IQR): 21.8), with the items of the methods and results sections having the worst reporting. Studies on neck pain had better adherence to the TRIPOD than studies on back pain and OA (medians of 76.5%, 59%, and 53%, respectively). External validation studies had the highest total adherence (median: 79.5%, IQR: 12.8) of all the study types. The median overall adherence was 4 points higher in studies that declared TRIPOD use than those that did not. Finally, we did not observe any improvement in adherence over the years. The adherence to the TRIPOD of prediction models in the spinal and OA fields is low, with the methods and results sections being the most poorly reported. Future studies on prediction models in spinal pain and OA should follow the TRIPOD to improve their reporting completeness. PERSPECTIVE: This article provides data about adherence to the TRIPOD statement in 66 prediction model studies for spinal pain or OA. The adherence to the TRIPOD statement was found to be low (median adherence of 59%). This inadequate reporting may negatively impact the effective use of the models in clinical practice.
A cannabinoid formulation comprising cannabinoid concentrate and beeswax, or a beeswax analogue, in a ratio of 30:1 to 40:1 by weight. Preferably the ratio is 35:1. The vaporizable formulation is packaged in a single use glass vial and used for pulmonary administration to a patient. The glass vial is made from borosilicate glass, has a cylindrical shape, an open end and no lid. The vial preferably has a uniform wall thickness of 0.02 inches. The formulation forms a wax seal at room temperature to eliminate any need for a lid. The formulation can be directly vaporized from the glass vial to eliminate transfer of the formulation to another container, to eliminate mess, to enable precise dosing, and to enable easy recycling and disposal of the vial after use.
In a healthy volunteer repeat-dose pharmacokinetic trial evaluating high-dose combinations of fosamprenavir calcium plus ritonavir, an increased frequency of Grade 2/3 ALT elevations (greater than 2.5 x ULN) was observed with fosamprenavir calcium 1,400 mg twice daily plus ritonavir 200 mg twice daily (4 of 25 subjects). Concurrent Grade 1/2 elevations in AST (greater than 1.25 x ULN) were noted in 3 of these 4 subjects. These transaminase elevations resolved following discontinuation of dosing. 

There is no known antidote for fosamprenavir calcium. It is not known whether amprenavir can be removed by peritoneal dialysis or hemodialysis, although it is unlikely as amprenavir is highly protein bound. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary.
FIELD: immunology, preparative biochemistry. SUBSTANCE: method of preparing immunoglobulin preparations with high titer involves the following successive stages: fractionation of blood plasma from plasma pool where fraction that has polyclonal immunoglobulin G and can be used in industry is separated; preparing protein solution from protein components; affinity chromatography carrying out. Obtained immunoglobulins can be processed to the preparation that can be used for intravenous administration and stable in storage. Method provides preparing immunoglobulin preparation from human plasma fractions that are not utilized in conventional methods of plasma fractionation early. EFFECT: improved method of preparing. 22 cl, 14 tbl, 10 ex
Background: The safety and efficacy of enhanced recovery after surgery (ERAS) following elective gastrectomy for gastric cancer in patients >80 years of age are not well described. The aim of this study was to explore whether an ERAS protocol following gastrectomy in this age group can be safely implemented and reduce postoperative length of stay. Methods: A retrospective, single-center analysis was performed. All patients >80 years of age with gastric cancer undergoing elective subtotal and total gastrectomy between January 2010 and December 2021 were identified. With the implementation of an ERAS protocol in January 2016, patients treated beforehand were allocated to Group A (pre-ERAS) and Group B (ERAS). The length of stay, incidence of postoperative complications and representation/readmission to the hospital were compared between the groups. Results: Of the 221 patients identified, 56 met the inclusion criteria with 22 patients (39.3%) allocated to Group A and 34 patients (60.7%) to Group B. There were no differences with regard to the type of resection and surgical approach. Length of stay was shorter in Group B (5 days, range 2-27 versus 10 days, 3-109, P = .040). A trend toward more discharges by postoperative day 3 was noted among patients in Group B (7/34, 20.6% versus 2/22, 9.1%, P = .253). There were no differences in the incidence of postoperative complications or readmission hospital between the groups. Conclusion: Among patients >80 years of age, ERAS following gastrectomy for cancer is associated with a reduced length of stay and can be safely implemented.
The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs.

Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder.

In patients with gastroesophageal reflux and low LESP (lower esophageal sphincter pressure), single oral doses of metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (the largest dose tested). The increase in LESP from a 5 mg dose lasts about 45 minutes and that of 20 mg lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg.

The antiemetic properties of metoclopramide appear to be a result of its antagonism of central and peripheral dopamine receptors. Dopamine produces nausea and vomiting by stimulation of the medullary chemoreceptor trigger zone (CTZ), and metoclopramide blocks stimulation of the CTZ by agents like l-dopa or apomorphine which are known to increase dopamine levels or to possess dopamine-like effects. Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.

Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions, although these are comparatively rare (see WARNINGS). Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention. 

The onset of pharmacological action of metoclopramide is 1 to 3 minutes following an intravenous dose, 10 to 15 minutes following intramuscular administration, and 30 to 60 minutes following an oral dose, pharmacological effects persist for 1 to 2 hours.
PURPOSE:A hair protecting agent, consisting of a specific quaternary trimethylammonium-derived polypeptide, capable of exhibiting improved hair protecting action, and preventing hair damage by cosmetics, e.g. permanent waving agent or shampoo, etc. CONSTITUTION:A hair protecting agent consisting of a compound expressed by formula I (R is side chain of amino acid constituting polypeptide derived from animal proteins; n is 3-20). The above-mentioned compound is obtained by reacting a compound expressed by formula II with a compound expressed by formula III, and has polypeptide part derived from animal proteins, e.g. collagen, keratin or silk protein, and chemical structure similar to that of the hair, and action of adsorbing on the hair by the action of the amino groups, carboxyl groups and further side chains of various amino acids to protect the hair and regenerate damaged hair. The quaternization improves the adsorbability of the agent on the hair greatly to impart flexibility of high order and natural gloss to the hair.